Nanomedicine: Past, present and future – A global perspective

Chang, Esther H.; Harford, Joe B.; Eaton, Michael A. W.; Boisseau, P.; Dube, Admire; Hayeshi, Rose; Swai, Hulda; Lee, Dong Hoon

doi:10.1016/j.bbrc.2015.10.136

Cited by 126 publications

(78 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, the terms “nanomaterial” and “nanosystem” include a wide variety of objects with at least one dimension in the nanometric scale (typically 1–1000 nm) (Figure 1). The term nanomedicine appeared in the 1990s, and since then, its interest has experienced an exponential increase within the scientific community, notably during the last 20 years, after the government of the United States announced that it was starting to fund nanomedicinal studies [7,8,14,15,16,17,18,19,20,21]. More recently, the European Technology platform on Nanomedicine (ETPN) defined the term “nanomedicine” as: “The application of nanotechnology to achieve breakthroughs in healthcare that exploits the improved and often novel physical, chemical and biological properties of materials at the nanometer scale” [4].…”

Section: Introductionmentioning

confidence: 99%

“…Although many types of nanomedicines exist, i.e., polymeric nanosystems, nanoparticles, magnetic nanoparticles, and liposomes, for example (Figure 2), all of them present common advantages among conventional therapies; which in general modify the pharmacokinetics and pharmacodynamics (pK/pD) of the active principles [23]. Specifically, these advantages can be grouped as follows (summarized in Table 1): (1) the size of the nanomaterials is very small, thus resulting in a large surface-to-volume ratio that is advantageous for the fine tuning of the nanomaterial’s surface; (2) activities of a different nature (lipophilic or hydrophilic) can be encapsulated in any type of nanosystem, thus enabling higher doses not possible in traditional therapies due to solubility problems; (3) they protect the encapsulated activities from the environment (e.g., light, nucleases); (4) they modify the pharmacokinetics of the active principles, allowing a controlled active release, which is advantageous to reduce the frequency of dosage and prolong the therapeutic activity; (5) they can be actively directed to the target organ, thus making possible a local therapeutic effect, increasing the therapeutic activity and reducing side effects; (6) the possibility of choosing among different nanosystem types gives nanomedicine the appropriate versatility to design the appropriate specific treatment to achieve a personalized therapy [4,12,15,17,18,19,20,26,27,30,31,32,33]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Personalized Nanomedicine: A Revolution at the Nanoscale

Fornaguera

García-Celma

2017

JPM

116

View full text Add to dashboard Cite

Nanomedicine is an interdisciplinary research field that results from the application of nanotechnology to medicine and has the potential to significantly improve some current treatments. Specifically, in the field of personalized medicine, it is expected to have a great impact in the near future due to its multiple advantages, namely its versatility to adapt a drug to a cohort of patients. In the present review, the properties and requirements of pharmaceutical dosage forms at the nanoscale, so-called nanomedicines, are been highlighted. An overview of the main current nanomedicines in pre-clinical and clinical development is presented, detailing the challenges to the personalization of these therapies. Next, the process of development of novel nanomedicines is described, from their design in research labs to their arrival on the market, including considerations for the design of nanomedicines adapted to the requirements of the market to achieve safe, effective, and quality products. Finally, attention is given to the point of view of the pharmaceutical industry, including regulation issues applied to the specific case of personalized medicine. The authors expect this review to be a useful overview of the current state of the art of nanomedicine research and industrial production, and the future opportunities of personalized medicine in the upcoming years. The authors encourage the development and marketing of novel personalized nanomedicines.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Personalized Nanomedicine: A Revolution at the Nanoscale

Fornaguera

García-Celma

2017

JPM

116

View full text Add to dashboard Cite

show abstract

“…14,15 In this context, rapid growth in nanotechnology toward the development of nanomedicine products holds great promise for cancer therapy. 16,17 Nanomedicines have unique properties, such as high surface-to-volume ratio and favorable physicochemical characteristics. [18][19][20] These properties can improve the pharmacokinetics and pharmacodynamics of conventional therapeutics and optimize the efficacy of existing anticancer compounds.…”

Section: Introductionmentioning

confidence: 99%

In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

Yang¹,

Zhang²,

Gong³

et al. 2016

IJN

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. In this study, sorafenib-loaded lipid-based nanosuspensions (sorafenib-LNS) were first developed as an intravenous injectable formulation to increase the efficacy of sorafenib against HCC. LNS were used as nanocarriers for sorafenib owing to their desired features in increasing the solubility and dissolution velocity, improving the bioavailability of sorafenib. Sorafenib-LNS were prepared by nanoprecipitation and consisted of spherical particles with a uniform size distribution (164.5 nm, polydispersity index =0.202) and negative zeta potential (−11.0 mV). The drug loading (DL) was 10.55%±0.16%. Sorafenib-LNS showed higher in vitro cytotoxicity than sorafenib against HepG2 cells ( P <0.05) and Bel-7402 cells ( P <0.05). The in vivo biodistribution, biocompatibility, and antitumor efficacy of sorafenib-LNS were evaluated in H22-bearing liver cancer xenograft murine model. The results showed that sorafenib-LNS (9 mg/kg) exhibited significantly higher antitumor efficacy by reducing the tumor volume compared with the sorafenib oral group (18 mg/kg, P <0.05) and sorafenib injection group (9 mg/kg, P <0.05). Furthermore, the results of the in vivo biodistribution experiments demonstrated that sorafenib-LNS injected into H22 tumor-bearing mice exhibited increased accumulation in the tumor tissue, which was confirmed by in vivo imaging. In the current experimental conditions, sorafenib-LNS did not show significant toxicity both in vitro and in vivo. These results suggest that sorafenib-LNS are a promising nanomedicine for treating HCC.

show abstract

“…Las NP tienen propiedades físicas y químicas únicas como su pequeño tamaño, gran área superficial, alta relación de aspecto, o sea, la proporción entre su ancho y su altura, lo que permite que tengan gran potencial para diferentes aplicaciones biomédicas (1,2). La nanomedicina es la aplicación de la nanotecnología para el diagnóstico y tratamiento de enfermedades, y para el monitoreo y control de sistemas biológicos, un área interdisciplinaria de la investigación en ciencias básicas, ingeniería y medicina (2,4,6,7).…”

Section: Introductionunclassified

“…La nanomedicina es la aplicación de la nanotecnología para el diagnóstico y tratamiento de enfermedades, y para el monitoreo y control de sistemas biológicos, un área interdisciplinaria de la investigación en ciencias básicas, ingeniería y medicina (2,4,6,7).…”

Section: Introductionunclassified

Efecto inmunomodulador de nanopartículas usadas en nanomedicina

Gómez-Gallego

Urcuqui-Inchima

Hernández

2016

iatreia

View full text Add to dashboard Cite

RESUMENLas nanopartículas (NP) son estructuras con tamaño en la escala nanométrica (1 x 10 -9 m). Por sus características, en los últimos años ha crecido su potencial para usarlas en los campos biotecnológico y biomédico en una amplia gama de aplicaciones, tales como el diagnóstico, la terapia y la medicina regenerativa.El sistema inmunológico es el responsable de la defensa del cuerpo ante organismos patógenos y otros agentes extraños, como las NP, que pueden ser reconocidas por dicho sistema, interactuar con él y modular su función induciendo efectos inmunosupresores o inmunoestimuladores. Las primeras se podrían utilizar como agentes terapéuticos antinflamatorios o para tratar las enfermedades autoinmunes, y las que activan el sistema inmune, como adyuvantes en vacunación o potenciadores de la respuesta inmune en cáncer y otras enfermedades humanas. Sin embargo, su uso en nanomedicina debe estar sujeto a ensayos previos que determinen su efecto en la respuesta inmune antes de aplicarlas a los sistemas biológicos. Por esta razón es importante conocer su composición, tamaño y características superficiales, entre otras propiedades fisicoquímicas, directamente implicadas en los efectos sobre el sistema inmune. Se presenta una visión general de la relación entre las propiedades fisicoquímicas de las NP candidatas para ser usadas en los campos biomédico y biotecnológico y su actividad inmunomoduladora. PALABRAS CLAVEInmunomodulación; Nanomedicina; Nanopartículas SUMMARYImmunomodulating effect of nanoparticles used in nanomedicine Nanoparticles (NP) are structures with a size on the nanometer scale (1 x 10 -9 m). Due to their characteristics, their potential use in the fields of biotechnology and biomedicine has grown in

show abstract

Nanomedicine: Past, present and future – A global perspective

Cited by 126 publications

References 15 publications

Personalized Nanomedicine: A Revolution at the Nanoscale

Personalized Nanomedicine: A Revolution at the Nanoscale

In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

Efecto inmunomodulador de nanopartículas usadas en nanomedicina

Contact Info

Product

Resources

About